Christopher van Tuyl - 26 Jun 2026 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
26 Jun 2026, 19:45:00 UTC
Prior SEC filing
22 Jun 2026
Next SEC filing
10 Jul 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Tiago Girao, attorney-in-fact for Christopher Van Tuyl

Key filing fact

Christopher van Tuyl filed Form 4 for Immunovant, Inc. (IMVT) on 26 Jun 2026.

Key facts

  • This page summarizes Christopher van Tuyl's Form 4 filing for Immunovant, Inc. (IMVT).
  • 4 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 26 Jun 2026, 19:45.

Change

  • Previous filing in this sequence was filed on 22 Jun 2026.
  • Current net transaction value: -$682,887.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001779707 Primary reporting owner

Van Tuyl Christopher

Relationship
Chief Legal Officer
Address
C/O IMMUNOVANT, INC., 1000 PARK FORTY PLAZA, SUITE 210, DURHAM
Signature
/s/ Tiago Girao, attorney-in-fact for Christopher Van Tuyl
Signature date
26 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMVT transaction

Common Stock

Options Exercise

Transaction value
Shares
+17,824
Change %
+9.9%
Price
$15.20*
Shares after
198,421
Date
26 Jun 2026
Ownership
Direct
IMVT transaction

Common Stock

Sale

Transaction value
$572,163
Shares
-14,982
Change %
-7.6%
Price
$38.19
Shares after
183,439
Date
26 Jun 2026
Ownership
Direct
Footnotes
F1
IMVT transaction

Common Stock

Sale

Transaction value
$110,724
Shares
-2,842
Change %
-1.5%
Price
$38.96
Shares after
180,597
Date
26 Jun 2026
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMVT transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-17,824
Change %
-25%
Price
$0.000000*
Shares after
53,707
Date
26 Jun 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
17,824
Exercise price
$15.20
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.75 - $38.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Footnote F2

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.82 - $39.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Footnote F3

Award of stock options to purchase Common Shares with a grant date of April 1, 2025. The shares underlying the option vest as to 25% on April 1, 2026, with the remainder vesting in 36 successive substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continued service to the Issuer as of such date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .